Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Palliative Care × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Weight Loss 1 Obesity 1 Neuroendocrine Tumors 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

lutetium Lu 177 dotatate 40 Everolimus 35 Magnetic Resonance Spectroscopy 15 lanreotide 14 gallium Ga 68 dotatate 13 Temozolomide 13 Octreotide 12 Nivolumab 12 pembrolizumab 11 Capecitabine 11 surufatinib 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Sunitinib 8 Specimen Handling 7 Carboplatin 7 telotristat ethyl 6 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Ipilimumab 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01849523 2024-05-06

WIN

University Medical Center Groningen

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡